(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

The pharmaceutical company Amgen announced Wednesday that it will decrease the price of its cholesterol lowering drug Repatha by 60%. The company said some patients weren't filling their prescriptions ...

SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

(Reuters) - Amgen Inc , looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the biotechnology company said on Wednesday.

Amgen is cutting the list price of its cholesterol drug Repatha by 60% to $5,850 in an unprecedented move to make the drug available to senior citizens. “We’ve got to make sure those who need [Repatha ...